Literature for peptidase M27.002: bontoxilysin

(References are filtered for relevance to Therapeutic. To remove the filter click here. See explanation.)

2019
1. Elliott,M., Favre-Guilmard,C., Liu,S.M., Maignel,J., Masuyer,G., Beard,M., Boone,C., Carre,D., Kalinichev,M., Lezmi,S., Mir,I., Nicoleau,C., Palan,S., Perier,C., Raban,E., Zhang,S., Dong,M., Stenmark,P. and Krupp,J.
   Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models
   Sci Adv5, eaau7196-eaau7196. PubMed  Europe PubMed DOI  U
2. Kerscher,M., Wanitphakdeedecha,R., Trindade de Almeida,A., Maas,C. and Frevert,J.
   IncobotulinumtoxinA: a highly purified and precisely manufactured Botulinum neurotoxin type A
   J Drugs Dermatol18, 52-57. PubMed  Europe PubMed  U
2017
3. Awan,K.H.
   The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions - An evidence based review
   Saudi Pharm J25, 18-24. PubMed  Europe PubMed DOI  U
4. Olbrich,K., Costard,L., Moser,C.V., Syhr,K.M., King-Himmelreich,T.S., Wolters,M.C., Schmidtko,A., Geisslinger,G. and Niederberger,E.
   Cleavage of SNAP-25 ameliorates cancer pain in a mouse model of melanoma
   Eur J Pain21, 101-111. PubMed  Europe PubMed DOI  U
5. Wang,J., Casals-Diaz,L., Zurawski,T., Meng,J., Moriarty,O., Nealon,J., Edupuganti,O.P. and Dolly,O.
   A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain
   Neuropharmacology118, 223-232. PubMed  Europe PubMed DOI  U
2016
6. Vazquez-Cintron,E., Tenezaca,L., Angeles,C., Syngkon,A., Liublinska,V., Ichtchenko,K. and Band,P.
   Pre-clinical study of a novel recombinant Botulinum neurotoxin derivative engineered for improved safety
   Sci Rep6, 30429-30429. PubMed  Europe PubMed DOI  U
2013
7. Bigalke,H.
   Botulinum toxin: application, safety, and limitations
   Curr Top Microbiol Immunol364, 307-317. PubMed  Europe PubMed DOI  U
8. Hawlitschka,A., Antipova,V., Schmitt,O., Witt,M., Benecke,R., Mix,E. and Wree,A.
   Intracerebrally applied Botulinum neurotoxin in experimental neuroscience
   Curr Pharm Biotechnol14, 124-130. PubMed  Europe PubMed  U
2012
9. Dolly,J.O. and O'Connell,M.A.
   Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain
   Curr Opin Pharmacol12, 100-108. PubMed  Europe PubMed DOI  U
10. Peng Chen,Z., Morris,J.G., Rodriguez,R.L., Shukla,A.W., Tapia-Nunez,J. and Okun,M.S.
    Emerging opportunities for serotypes of botulinum neurotoxins
    Toxins (Basel)4, 1196-1222. PubMed  Europe PubMed DOI  U
11. Somm,E., Bonnet,N., Martinez,A., Marks,P.M., Cadd,V.A., Elliott,M., Toulotte,A., Ferrari,S.L., Rizzoli,R., Huppi,P.S., Harper,E., Melmed,S., Jones,R. and Aubert,M.L.
    A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis
    J Clin Invest122, 3295-3306. PubMed  Europe PubMed DOI  U
12. Tajti,J., Szok,D., Tuka,B., Csati,A., Kuris,A., Majlath,Z., Lukacs,M. and Vecsei,L.
    [Botulinum neurotoxin - a therapy in migraine]
    Ideggyogy Sz65, 77-82. PubMed  Europe PubMed  U
2011
13. Capek,P., Zhang,Y., Barlow,D.J., Houseknecht,K.L., Smith,G.R. and Dickerson,T.J.
    Enhancing the pharmacokinetic properties of botulinum neurotoxin serotype A protease inhibitors through rational design
    ACS Chem Neurosci2, 288-293. PubMed  Europe PubMed DOI  U
14. Yu,H.M., Li,Q., Zhou,X.D., Perelman,J.M. and Kolosov,V.P.
    Expression of recombinant fusion protein BoNT-LH (N)-elafin in Pichia pastoris and activity of expressed product
    Chin J Biol24, 389-393.  U
2010
15. Carmichael,N.M., Dostrovsky,J.O. and Charlton,M.P.
    Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin
    Pain149, 316-324. PubMed  Europe PubMed DOI  U
16. Hexsel,D., Spencer,J.M., Woolery-Lloyd,H. and Gilbert,E.
    Practical applications of a new botulinum toxin
    J Drugs Dermatol9, s31-s37. PubMed  Europe PubMed  U
2009
17. Chen,S. and Barbieri,J.T.
    Engineering botulinum neurotoxin to extend therapeutic intervention
    Proc Natl Acad Sci U S A106, 9180-9184. PubMed  Europe PubMed DOI  U
2008
18. Wohlfarth,K., Schwandt,I., Wegner,F., Jurgens,T., Gelbrich,G., Wagner,A., Bogdahn,U. and Schulte-Mattler,W.
    Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study
    J Neurol255, 1932-1939. PubMed  Europe PubMed DOI  U
1989
19. Scott,A.B.
    Clostridial toxin as therapeutic agents
    399-412.  U